Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) today announced a global partnership pairing Abbott CGMs with Medtronic insulin delivery systems. The partnership aims to collaborate on a system based on Abbott’s FreeStyle Libre continuous glucose monitors (CGMs) with Medtronic’s automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as […]
abbott
Abbott recalls some FreeStyle Libre 3 sensors in U.S.
Abbott (NYSE:ABT) announced today that it initiated a voluntary recall for a small number of FreeStyle Libre 3 continuous glucose monitor (CGM) sensors. The company distributed the affected sensors during the first half of May 2024. Abbott did not disclose the number of sensors affected but said the recall affects a small subset of FreeStyle […]
Report: Court says SiBio can’t sell CGM in some European countries amid Abbott IP battle
JUVE-Patent reports that The Hague recently handed down two new decisions in a CGM patent battle between Abbott and SiBio. One case saw an Abbott patent infringement application shot down, while the other granted the U.S. medtech giant’s claim. The granted one could mean SiBio can’t distribute its CGMs in Germany, France, the Netherlands and […]
The biggest stories from the American Diabetes Association (ADA) 2024 Scientific Sessions
The American Diabetes Association took to Orlando, Florida, the past few days for its 84th Scientific Sessions as optimism grows over diabetes tech. Topics covered included expanding technologies to the type 2 diabetes population (90% of people with diabetes), GLP-1 drugs, automation, broadening user bases and more. The usual big-hitters stepped up to the plate […]
Why Abbott acquired Bigfoot Biomedical and its smart insulin pens
When Abbott (NYSE:ABT) acquired Bigfoot Biomedical in September 2023, it took the final step to build upon a multi-year relationship. The medtech giant had a long-term, vested interest in Bigfoot, a maker of a smart insulin management system. It dates back to 2017, with Abbott even leading a financing round for Bigfoot in 2020. “We […]
Abbott targets type 2 diabetes with ‘exciting year’ ahead
The Diabetes business unit at Abbott (NYSE:ABT) has gotten off to a hot start in 2024, with some significant developments on the CGM front. With the recent FDA clearance of two over-the-counter sensors following significant automated insulin pump integrations, 2024 has been full of good news for the company. Speaking to Drug Delivery Business News at […]
Insulet fully launches Omnipod 5 with Dexcom G7 in the U.S. along with iPhone app
Insulet (Nasdaq:PODD) announced today that it began a full U.S. launch of Omnipod 5 with the Dexcom G7 continuous glucose monitor (CGM). The company also announced a series of launches and updates, including a limited release of the Omnipod 5 App for iPhone. Insulet also made Omnipod 5 available in France and launched the system […]
Abbott wins FDA clearance for duo of over-the-counter CGMs
Abbott (NYSE:ABT) today announced FDA clearance for two over-the-counter continuous glucose monitor (CGM) systems, Lingo and Libre Rio. The company built both systems on its FreeStyle Libre CGM technology, but both aim to meet different needs. Lingo offers consumers a solution to better understand and improve their health and wellness. Libre Rio provides monitoring for […]
Abbott wins FDA clearance for its Lingo OTC glucose monitor
Abbott (NYSE: ABT) has secured a 510(k) clearance from the FDA for its over-the-counter Lingo glucose-monitoring biowearable. The clearance came on May 29, according to a listing on the FDA’s website. An Abbott spokesperson said the company was aware of the clearance and would provide more details later. FDA clearance for Abbott’s Lingo comes more […]
Dexcom, Abbott ask for another trial in CGM patent spat
Abbott (NYSE:ABT) and Dexcom (Nasdaq:DXCM) both submitted legal briefs angling for another trial in an ongoing continuous glucose monitor (CGM) patent spat. In March, the U.S. District Court for the District of Delaware found that Dexcom violated a single patent belonging to Abbott and its FreeStyle Libre sensors. However, the court found that Dexcom did […]
